首页> 外文OA文献 >Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

【2h】

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

机译：安慰剂对照FASTACT-2Ⅲ期研究在晚期非小细胞肺癌一线治疗中联合厄洛替尼联合吉西他滨/铂的肿瘤标志物分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Mok Tony; Ladrera Guia; Srimuninnimit Vichien; Sriuranpong Virote; Yu Chong-Jen; Thongprasert Sumitra; Sandoval-Tan Jennifer; Lee Jin Soo; Fuerte Fatima; Shames David S.; Klughammer Barbara; Truman Matt; Perez-Moreno Pablo; Wu Yi-Long;
展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer [J] . Mok Tony, Ladrera Guia, Srimuninnimit Vichien, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：安慰剂对照FASTACT-2Ⅲ期研究在晚期非小细胞肺癌一线治疗中插入厄洛替尼联合吉西他滨/铂的肿瘤标志物分析
2. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer [J] . Mok Tony, Ladrera Guia, Srimuninnimit Vichien, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Null期

机译：肿瘤标志物从III期，安慰剂控制，与吉西他滨/铂在先进的非小细胞肺癌的一线治疗中与吉西他滨/铂的闭合尔洛尼替尼的闭合腹膜2研究
3. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial. [J] . Gridelli C, Butts C, Ciardiello F, Clinical lung cancer . 2008,第4期

机译：国际，多中心，随机，III期研究对晚期非小细胞肺癌一线埃罗替尼，二线顺铂/吉西他滨与一线顺铂/吉西他滨，二线埃洛替尼进行二线研究：治疗原理和方案动态TORCH审判。
4. Effects of Erlotinib after Acquired Resistance to Gefitinib in Advanced Non-small-cell Lung Cancer [C] . Pan Jingjing, Shi Meiqi, Feng Jifeng Biomedical Engineering and Biotechnology (iCBEB), 2012 International Conference on . 2012

机译：吉非替尼耐药对晚期非小细胞肺癌患者的厄洛替尼治疗效果
5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy [D] . 鈴木, 裕子 2019

机译：吉西他滨联合顺铂一线化疗对晚期胆道癌患者治疗效果的预测因素
6. Editors choice: Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized multicenter open-label phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer [O] . L. Paz-Ares, M. A. Socinski, J. Shahidi, -1

机译：编辑选择：SQUIRE中EGFR表达与安全性和疗效结果的相关性：吉西他滨-顺铂加尼妥单抗与单独吉西他滨-顺铂在IV期患者一线治疗中的随机多中心开放标签III期研究鳞状非小细胞肺癌
7. Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS) [O] . Kabbinavar Fairooz, Fehrenbacher Louis, Hainsworth John, 2014

机译：比较贝伐单抗联合或不联合厄洛替尼作为晚期非小细胞肺癌（ATLAS）维持治疗的随机安慰剂对照IIIb期临床试验的生物标志物分析

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

著录项

相似文献

相关主题

期刊订阅